Shidong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shidong Li has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
B. Micaily
Temple University
2 shared publicationsDavid Djajaputra
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
2 shared publicationsAbdul Rashid
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
1 shared publicationAndrew Hollander
Department of Radiation Oncology Temple University Hospital Philadelphia PA USA
1 shared publicationB. Movsas
Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA
1 shared publicationBin Wang
Department of Radiation Oncology Temple University Hospital Philadelphia PA USA
1 shared publication
Latest Publications
- Open Access
- 16 February 2021
- Published by Wiley in Medical Physics
- Vol. 48 (4) , 2038-2049
A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
Purpose: Application of linear‐quadratic (LQ) model to large fractional dose treatments is inconsistent with observed cell survival curves having a straight portion at high doses. We have proposed a unified multi‐activation (UMA) model to fit cell survival curves over the entire dose range that allows us to calculate EQD2 for hypofractionated SBRT, SRT, SRS, and HDRB.Methods: A unified formula of cell survival using only the extrapolation number of n and the dose slope of Do was derived. Coefficient of determination, R2, relative residuals, r, and relative experimental errors, e, normalized to survival fraction at each dose point, were calculated to quantify the goodness in modeling of a survival curve. Analytical solutions for α and β, the coefficients respectively describe the linear and quadratic parts of the survival curve, as well as the α/β ratio for the LQ model and EQD2 at any fractional doses were derived for tumor cells undertaking any fractionated radiation therapy.Results: Our proposed model fits survival curves of in‐vivo and in‐vitro tumor cells with R2 > 0.97 and r < e. The predicted α, β, and α/β ratio are significantly different from their values in the LQ model. Average EQD2 of 20‐Gy SRS of glioblastomas and melanomas metastatic to the brain, 10‐Gy × 5 SBRT of the lung cancer, and 7‐Gy × 5 HDRB of endometrial and cervical carcinomas are 36.7 (24.3–48.5), 114.1 (86.6–173.1),, and 45.5 (35–52.6) Gy, different from the LQ model estimates of 50.0, 90.0, and 49.6 Gy, respectively.Conclusion: Our UMA model validated through many tumor cell lines can fit cell survival curves over the entire dose range within their experimental errors. The unified formula theoretically indicates a common mechanism of cell inactivation and can estimate EQD2 at all dose levels.
- 16 February 2021
- Published by Wiley in Medical Physics
- Vol. 48 (4) , 2038-2049
Open AccessA unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)
Purpose: Application of linear‐quadratic (LQ) model to large fractional dose treatments is inconsistent with observed cell survival curves having a straight portion at high doses. We have proposed a unified multi‐activation (UMA) model to fit cell survival curves over the entire dose range that allows us to calculate EQD2 for hypofractionated SBRT, SRT, SRS, and HDRB.Methods: A unified formula of cell survival using only the extrapolation number of n and the dose slope of Do was derived. Coefficient of determination, R2, relative residuals, r, and relative experimental errors, e, normalized to survival fraction at each dose point, were calculated to quantify the goodness in modeling of a survival curve. Analytical solutions for α and β, the coefficients respectively describe the linear and quadratic parts of the survival curve, as well as the α/β ratio for the LQ model and EQD2 at any fractional doses were derived for tumor cells undertaking any fractionated radiation therapy.Results: Our proposed model fits survival curves of in‐vivo and in‐vitro tumor cells with R2 > 0.97 and r < e. The predicted α, β, and α/β ratio are significantly different from their values in the LQ model. Average EQD2 of 20‐Gy SRS of glioblastomas and melanomas metastatic to the brain, 10‐Gy × 5 SBRT of the lung cancer, and 7‐Gy × 5 HDRB of endometrial and cervical carcinomas are 36.7 (24.3–48.5), 114.1 (86.6–173.1),, and 45.5 (35–52.6) Gy, different from the LQ model estimates of 50.0, 90.0, and 49.6 Gy, respectively.Conclusion: Our UMA model validated through many tumor cell lines can fit cell survival curves over the entire dose range within their experimental errors. The unified formula theoretically indicates a common mechanism of cell inactivation and can estimate EQD2 at all dose levels.
- Open Access
- 1 January 2021
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 3 (1)
Theoretical derivation and clinical dose-response quantification of a unified multi-activation (UMA) model of cell survival from a logistic equation
Objective: To theoretically derive a unified multiactivation (UMA) model of cell survival after ionising radiation that can accurately assess doses and responses in radiotherapy and X-ray imaging. Methods: A unified formula with only two parameters in fitting of a cell survival curve (CSC) is first derived from an assumption that radiation-activated cell death pathways compose the first- and second-order reaction kinetics. A logit linear regression of CSC data is used for precise determination of the two model parameters. Intrinsic radiosensitivity, biologically effective dose (BED), equivalent dose to the traditional 2 Gy fractions (EQD2), tumour control probability, normal-tissue complication probability, BED50 and steepness (Γ50) at 50% of tumour control probability (or normal-tissue complication probability) are analytical functions of the model and treatment (or imaging) parameters. Results: The UMA model has almost perfectly fit typical CSCs over the entire dose range with R2≥0.99. Estimated quantities for stereotactic body radiotherapy of early stage lung cancer and the skin reactions from X-ray imaging agree with clinical results. Conclusion: The proposed UMA model has theoretically resolved the catastrophes of the zero slope at zero dose for multiple target model and the bending curve at high dose for the linear quadratic model. More importantly, it analytically predicts dose–responses to various dose–fraction schemes in radiotherapy and to low dose X-ray imaging based on these preclinical CSCs. Advances in knowledge: The discovery of a unified formula of CSC over the entire dose range may reveal a common mechanism of the first- and second-order reaction kinetics among multiple CD pathways activated by ionising radiation at various dose levels.
- 1 January 2021
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 3 (1)
Open AccessTheoretical derivation and clinical dose-response quantification of a unified multi-activation (UMA) model of cell survival from a logistic equation
Objective: To theoretically derive a unified multiactivation (UMA) model of cell survival after ionising radiation that can accurately assess doses and responses in radiotherapy and X-ray imaging. Methods: A unified formula with only two parameters in fitting of a cell survival curve (CSC) is first derived from an assumption that radiation-activated cell death pathways compose the first- and second-order reaction kinetics. A logit linear regression of CSC data is used for precise determination of the two model parameters. Intrinsic radiosensitivity, biologically effective dose (BED), equivalent dose to the traditional 2 Gy fractions (EQD2), tumour control probability, normal-tissue complication probability, BED50 and steepness (Γ50) at 50% of tumour control probability (or normal-tissue complication probability) are analytical functions of the model and treatment (or imaging) parameters. Results: The UMA model has almost perfectly fit typical CSCs over the entire dose range with R2≥0.99. Estimated quantities for stereotactic body radiotherapy of early stage lung cancer and the skin reactions from X-ray imaging agree with clinical results. Conclusion: The proposed UMA model has theoretically resolved the catastrophes of the zero slope at zero dose for multiple target model and the bending curve at high dose for the linear quadratic model. More importantly, it analytically predicts dose–responses to various dose–fraction schemes in radiotherapy and to low dose X-ray imaging based on these preclinical CSCs. Advances in knowledge: The discovery of a unified formula of CSC over the entire dose range may reveal a common mechanism of the first- and second-order reaction kinetics among multiple CD pathways activated by ionising radiation at various dose levels.
- Open Access
- 1 August 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1305 (1) , 012060
Characteristics of popular photon beam collimators
Purpose: To compare the physical and dosimetric aspects of radiation beam collimation systems that may affect the stereotactic radiosurgery and radiotherapy of small lesions. Methods: Gamma knife (GK) cones, Cyber-knife Iris/InCise collimators, popular Varian and Elekta multi-leaf collimators (MLCs) were theoretically analyzed. Leaf-edge effects (Inter- and intra-leaf leakages, field penumbras, and dosimetric leaf gap - DLG) and transmission through some collimators were measured with ion chambers and films in phantoms and electronic portal imagers in an extended distance. GK plans and IMRT/VMAT plans were generated for ten patients and conformity index (CI) and dose drop (DD) from target to 5-mm ring were compared. Results: New MLCs have improved field shaping conformity, reduced transmission but not field penumbra and DLG. The measured DLG changed with time of usage and varied across the field. GK plans had better CI and DD for small lesions of < 1 cm while MLC-based VMAT/IMRT plans improved CI for large lesions of > 2 cm. Conclusions: New thinner and taller MLCs have improved the field shaping conformity and transmission but not leaf edge effects. Cone-based irradiation is still the best to small lesions of < 1 cm while VMAT/IMRT using new MLCs provide more conformal dose to irregular target usually with size of > 2 cm.
- 1 August 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1305 (1) , 012060
Open AccessCharacteristics of popular photon beam collimators
Purpose: To compare the physical and dosimetric aspects of radiation beam collimation systems that may affect the stereotactic radiosurgery and radiotherapy of small lesions. Methods: Gamma knife (GK) cones, Cyber-knife Iris/InCise collimators, popular Varian and Elekta multi-leaf collimators (MLCs) were theoretically analyzed. Leaf-edge effects (Inter- and intra-leaf leakages, field penumbras, and dosimetric leaf gap - DLG) and transmission through some collimators were measured with ion chambers and films in phantoms and electronic portal imagers in an extended distance. GK plans and IMRT/VMAT plans were generated for ten patients and conformity index (CI) and dose drop (DD) from target to 5-mm ring were compared. Results: New MLCs have improved field shaping conformity, reduced transmission but not field penumbra and DLG. The measured DLG changed with time of usage and varied across the field. GK plans had better CI and DD for small lesions of < 1 cm while MLC-based VMAT/IMRT plans improved CI for large lesions of > 2 cm. Conclusions: New thinner and taller MLCs have improved the field shaping conformity and transmission but not leaf edge effects. Cone-based irradiation is still the best to small lesions of < 1 cm while VMAT/IMRT using new MLCs provide more conformal dose to irregular target usually with size of > 2 cm.
- 1 January 2013
- Published by Springer Nature
- p. 1628-1631
Spatial and Temporal Thermal Dose Distribution in Hyperthermia Therapy
- 1 January 2013
- Published by Springer Nature
- p. 1628-1631
Spatial and Temporal Thermal Dose Distribution in Hyperthermia Therapy
- 1 January 2013
- Published by Springer Nature
- p. 1949-1952
4D-Video Usefulness For Tracking Respiration Motion in 4DCT Scans and Targeting Small Mobile Tumors
- 1 January 2013
- Published by Springer Nature
- p. 1949-1952
4D-Video Usefulness For Tracking Respiration Motion in 4DCT Scans and Targeting Small Mobile Tumors
- Open Access
- 1 February 2012
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 11 (1) , 57-68
Initial Validation and Clinical Experience with 3D Optical-Surface-Guided Whole Breast Irradiation of Breast Cancer
We had introduced 3D optical surface-guided radiotherapy (SGRT) of the breast cancer (BC). We then initiated the feasibility, accuracy, and precision studies of stereovision in detection of any breast displacement through the course of treatment for total thirty breasts undertaken whole breast irradiation (WBI). In the SGRT, CT-based plan data were parsed into an in-house computer program through which the reference surfaces were generated in 3D video format. When patients were positioned on treatment Tables, real-time stereovisions were rapidly acquired while the live surface tracking shown steady thorax motion. The real-time surface images were automatically aligned with the reference surface and detected shape and location changes of the breast were online corrected through the Table and beam adjustments. Accumulated dose to each patient was computed according to the frequency distribution of the measured breast locations during beam on time. Application of SGRT had diminished large skin-marking errors of >5-mm and daily breast-setup errors of >10-mm that occurred on half of cases. Accuracy (mean) and precision (two standard deviations) of the breast displacements across the tangential field edges in the (U, V) directions were improved from (−0.5 ± 8.8, 2.2 ± 10.8) mm in conventional setup to (0.4 ± 4.6, 0.7 ± 4.4) mm in the final position while intra-fractional motion contributed only (0.1 ± 2.8, 0.0 ± 2.2) mm in free breathing. Dose uniformity and coverage to targets had both been increased by up to 10% and the lung or heart intersections have been decreased by half of those volumes if they were irradiated at the initial positions. SGRT of BC appears to be feasible regardless of skin tones, as fast as a snapshot for 3D imaging, and very accurate and precise for daily setup of flexible breast targets. Importantly, the technique allows us to verify the breast shape and position during beam-on time.
- 1 February 2012
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 11 (1) , 57-68
Open AccessInitial Validation and Clinical Experience with 3D Optical-Surface-Guided Whole Breast Irradiation of Breast Cancer
We had introduced 3D optical surface-guided radiotherapy (SGRT) of the breast cancer (BC). We then initiated the feasibility, accuracy, and precision studies of stereovision in detection of any breast displacement through the course of treatment for total thirty breasts undertaken whole breast irradiation (WBI). In the SGRT, CT-based plan data were parsed into an in-house computer program through which the reference surfaces were generated in 3D video format. When patients were positioned on treatment Tables, real-time stereovisions were rapidly acquired while the live surface tracking shown steady thorax motion. The real-time surface images were automatically aligned with the reference surface and detected shape and location changes of the breast were online corrected through the Table and beam adjustments. Accumulated dose to each patient was computed according to the frequency distribution of the measured breast locations during beam on time. Application of SGRT had diminished large skin-marking errors of >5-mm and daily breast-setup errors of >10-mm that occurred on half of cases. Accuracy (mean) and precision (two standard deviations) of the breast displacements across the tangential field edges in the (U, V) directions were improved from (−0.5 ± 8.8, 2.2 ± 10.8) mm in conventional setup to (0.4 ± 4.6, 0.7 ± 4.4) mm in the final position while intra-fractional motion contributed only (0.1 ± 2.8, 0.0 ± 2.2) mm in free breathing. Dose uniformity and coverage to targets had both been increased by up to 10% and the lung or heart intersections have been decreased by half of those volumes if they were irradiated at the initial positions. SGRT of BC appears to be feasible regardless of skin tones, as fast as a snapshot for 3D imaging, and very accurate and precise for daily setup of flexible breast targets. Importantly, the technique allows us to verify the breast shape and position during beam-on time.
- Open Access
- 1 December 2010
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 9 (6) , 603-617
Clinical Results of a Pilot Study on Stereovision-Guided Stereotactic Radiotherapy and Intensity Modulated Radiotherapy
Real-time stereovision-guidance has been introduced for efficient and convenient fractionated stereotactic radiotherapy (FSR) and image-guided intensity-modulated radiation therapy (IMRT). This first pilot study is to clinically evaluate its accuracy and precision as well as impact on treatment doses. Sixty-one FSR patients wearing stereotactic masks (SMs) and nine IMRT patients wearing flexible masks (FMs), were accrued. Daily target reposition was initially based-on biplane-radiographs and then adjusted in six degrees of freedom under real-time stereovision guidance. Mean and standard deviation of the head displacements measured the accuracy and precision. Head positions during beam-on times were measured with real-time stereovisions and used for determination of delivered doses. Accuracy ± precision in direction with the largest errors shows improvement from 0.4 ± 2.3 mm to 0.0 ± 1.0 mm in the inferior-to-superior direction for patients wearing SM or from 0.8 ± 4.3 mm to 0.4 ± 1.7 mm in the posterior-to-anterior direction for patients wearing FM. The image-guidance increases target volume coverage by >30% for small lesions. Over half of head position errors could be removed from the stereovision-guidance. Importantly, the technique allows us to check head position during beam-on time and makes it possible for having frameless head refixation without tight masks.
- 1 December 2010
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 9 (6) , 603-617
Open AccessClinical Results of a Pilot Study on Stereovision-Guided Stereotactic Radiotherapy and Intensity Modulated Radiotherapy
Real-time stereovision-guidance has been introduced for efficient and convenient fractionated stereotactic radiotherapy (FSR) and image-guided intensity-modulated radiation therapy (IMRT). This first pilot study is to clinically evaluate its accuracy and precision as well as impact on treatment doses. Sixty-one FSR patients wearing stereotactic masks (SMs) and nine IMRT patients wearing flexible masks (FMs), were accrued. Daily target reposition was initially based-on biplane-radiographs and then adjusted in six degrees of freedom under real-time stereovision guidance. Mean and standard deviation of the head displacements measured the accuracy and precision. Head positions during beam-on times were measured with real-time stereovisions and used for determination of delivered doses. Accuracy ± precision in direction with the largest errors shows improvement from 0.4 ± 2.3 mm to 0.0 ± 1.0 mm in the inferior-to-superior direction for patients wearing SM or from 0.8 ± 4.3 mm to 0.4 ± 1.7 mm in the posterior-to-anterior direction for patients wearing FM. The image-guidance increases target volume coverage by >30% for small lesions. Over half of head position errors could be removed from the stereovision-guidance. Importantly, the technique allows us to check head position during beam-on time and makes it possible for having frameless head refixation without tight masks.
- 16 December 2004
- Published by Wiley in Medical Physics
- Vol. 32 (1) , 65-75
Real‐time 3D surface‐image‐guided beam setup in radiotherapy of breast cancer
We describe an approach for external beam radiotherapy of breast cancer that utilizes the three-dimensional (3D) surface information of the breast. The surface data of the breast are obtained from a 3D optical camera that is rigidly mounted on the ceiling of the treatment vault. This 3D camera utilizes light in the visible range therefore it introduces no ionization radiation to the patient. In addition to the surface topographical information of the treated area, the camera also captures gray-scale information that is overlaid on the 3D surface image. This allows us to visualize the skin markers and automatically determine the isocenter position and the beam angles in the breast tangential fields. The field sizes and shapes of the tangential, supraclavicular, and internal mammary gland fields can all be determined according to the 3D surface image of the target. A least-squares method is first introduced for the tangential-field setup that is useful for compensation of the target shape changes. The entire process of capturing the 3D surface data and subsequent calculation of beam parameters typically requires less than 1 min. Our tests on phantom experiments and patient images have achieved the accuracy of 1 mm in shift and 0.5 degrees in rotation. Importantly, the target shape and position changes in each treatment session can both be corrected through this real-time image-guided system.
- 16 December 2004
- Published by Wiley in Medical Physics
- Vol. 32 (1) , 65-75
Real‐time 3D surface‐image‐guided beam setup in radiotherapy of breast cancer
We describe an approach for external beam radiotherapy of breast cancer that utilizes the three-dimensional (3D) surface information of the breast. The surface data of the breast are obtained from a 3D optical camera that is rigidly mounted on the ceiling of the treatment vault. This 3D camera utilizes light in the visible range therefore it introduces no ionization radiation to the patient. In addition to the surface topographical information of the treated area, the camera also captures gray-scale information that is overlaid on the 3D surface image. This allows us to visualize the skin markers and automatically determine the isocenter position and the beam angles in the breast tangential fields. The field sizes and shapes of the tangential, supraclavicular, and internal mammary gland fields can all be determined according to the 3D surface image of the target. A least-squares method is first introduced for the tangential-field setup that is useful for compensation of the target shape changes. The entire process of capturing the 3D surface data and subsequent calculation of beam parameters typically requires less than 1 min. Our tests on phantom experiments and patient images have achieved the accuracy of 1 mm in shift and 0.5 degrees in rotation. Importantly, the target shape and position changes in each treatment session can both be corrected through this real-time image-guided system.